CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

IRulya Therapeutics Inc.

IRLA
$33MMicro Cap

Next catalyst

Phase 3Q4 2026

Dexamethasone sodium phosphate

Ataxia Telangiectasia

Get an email about IRLA's next catalysts

Track IRulya Therapeutics (IRLA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 2 more upcoming events in our data (Phase 2 readout, earnings).See the timeline

Catalyst Timeline

3 upcoming, 0 past

Phase 3Next

Dexamethasone sodium phosphate Phase 3 Est. Readout

Q4 2026~QDexamethasone sodium phosphate105

Primary completion for Dexamethasone sodium phosphate trial (NCT06664853) in Ataxia Telangiectasia

Source
Phase 2

LAM-001 Phase 2 Est. Readout (INSPO-BOS)

December 2026~LAM-00130

Estimated primary completion for LAM-001 trial (NCT06018766) in Bronchiolitis Obliterans Syndrome. Topline data typically follows completion by weeks to months.

Source
Earnings

IRLA Earnings Report

March 2027~

Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.83 | FQ end Sep/2026 | Call: tbd

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaNEW HAVEN
Drug Pipeline

Frequently asked questions

What is in IRulya Therapeutics Inc.'s drug pipeline?→

CatalystAlert tracks 6 drug candidates in IRulya Therapeutics Inc.'s (IRLA) pipeline across Phase 3, Phase 2. Its lead program is Dexamethasone sodium phosphate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is IRulya Therapeutics Inc.'s next FDA catalyst?→

IRulya Therapeutics Inc.'s (IRLA) next tracked catalyst is a Phase 3 readout expected Q4 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track IRLA biotech catalysts?→

Add IRLA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IRulya Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply